Biotech Values

[mcbio]

AAVL—I would argue that the AVA-101 wet-AMD program is a longshot, regardless of where the trial sites are located.

Curious to hear more here. No position in AAVL but certainly following. Didn't the prior trial generally show pretty good efficacy on one shot out to 52 weeks? If replicated in the ongoing trial, wouldn't this be a significant advance beyond the current treatments that require much more frequent injections even if it's ultimately proven that more than one shot of AVA-101 will be needed? Also, the competition such as OPHT aren't direct competitors in that it seems like PDGF inhibition will be complementary to VEGF inhibition and not a direct replacement.